Abion signs iADC platform joint research, licensing deal with LigaChem Biosciences

• Abion entered a joint research and licensing deal with LigaChem Biosciences to co-develop an iADC drug candidate.
• The program combines Abion’s IFN-β mutein immunocytokine-antibody with LigaChem’s proprietary ADC platform for global development and commercialization.
• LigaChem secured exclusive rights. It can designate up to five targets under the agreement, effective immediately.
• Economics include an upfront payment, research funding, target-based milestones, and sales royalties. Financial terms were not disclosed.
• The contract was signed on Sept. 30, 2026. Duration runs through the end of royalty payments for the last product.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abion Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20260930900696), on September 30, 2026, and is solely responsible for the information contained therein.